Dr. Chris Tsai is the founder and CEO of BIONET Corp and GGA Corp. BIONET, established in 1999 and went public in 2007, has years of experience in cell therapy and regenerative medicine. For the past 20 years, BIONET Corp. has dedicated research efforts to develop a variety of stem cell applications including immunomodulation and respiratory diseases. Five years ago, a human clinical trial was initiated to study the utilization of stem cells to treat severe lung injury and sepsis caused by influenza, pneumonia, and acute respiratory distress syndrome (ARDS). Amidst the recent COVID-19 pandemic, it has already been observed that some of the most severely affected patients develop ARDS, and about half of these patients later die from ARDS-related complications. ARDS is becoming one of the leading causes of COVID-19 mortality. With knowledge and insights gained from extensive past experience, BIONET Corp’s large collection of stem cells can be expected to potentially treat 1.3 millions of affected patients when there is a lack of effective medications and/or vaccines to save lives in a much needed timely manner. BIONET Corp’s readily available stem cells can be expected to be used for global medical rescue.
GGA Corp., a subsidiary of BIONET that went public in 2012, is a leader and a pioneer in genetic testing, precision medicine and bioinformatics solution. With a CAP-accredited laboratory, we offer high quality genetic testing service, including those surrounding influenza virus and other respiratory infection and related-disorders. GGA Corp. continues its energy to understand how genetics plays a role in viral infection susceptibility, vaccination reaction as well as immune response systems. With this knowledge in hand, genetic testing can be developed to help people better combat viruses and infections not just in time of pandemic crisis, like COVID-19, but also during routine daily life.